Targeting a diverse spectrum of cancers.

Kinase switch control inhibitors for tumor-targeted and immune-targeted cancer therapies.

Platform

Deciphera’s proprietary switch control platform has generated a diverse clinical pipeline of kinase inhibitor drug candidates including tumor-targeted therapies and immuno-targeted therapies.

Investors

DCPH

$22.73

2.15
11/15/18 4:00 PM EDT
© Nasdaq. Minimum 15 minutes delayed.

Latest News

Nov
15
2018
Deciphera Pharmaceuticals Completes Enrollment in the INVICTUS Pivotal Phase 3 Clinical Study of DCC-2618 in Patients with Advanced Gastrointestinal Stromal Tumors Read More »
Nov
08
2018
Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2018 Financial Results Read More »
Oct
23
2018
Deciphera Pharmaceuticals Initiates a Phase 1b/2 Clinical Trial of Rebastinib in Combination with Paclitaxel to Assess Safety, Tolerability, Pharmacokinetics and Efficacy in Patients with Advanced or Metastatic Solid Tumors Read More »